Ravi Shridhar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ravi Shridhar has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Kenneth L. Meredith
Department of Surgical Oncology, Sarasota Memorial Hospital, Sarasota, FL, USA
6 shared publicationsSarah E. Hoffe
Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
5 shared publicationsGregory M. Springett
Gastrointestinal Tumor Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
4 shared publicationsJamie Huston
Department of Surgical Oncology, Sarasota Memorial Hospital, Sarasota, FL, USA
3 shared publicationsMokenge P. Malafa
Gastrointestinal Tumor Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
3 shared publicationsPamela Hodul
University of South Florida Morsani College of Medicine, Tampa, FL, USA ; 2 Department of Radiation Oncology, 3 Gastrointestinal Tumor Program, 4 Senior Adult Oncology Program, Moffitt Cancer Center, Tampa, FL, USA ; 5 Gastrointestinal Oncology, Sarasota Memorial Hospital, Sarasota, FL, USA
3 shared publications
Latest Publications
- 1 August 2019
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 10 (4) , 663-673
Neoadjuvant therapy and pancreatic cancer: a national cancer database analysis
Background: We sought to examine the impact of neoadjuvant chemotherapy (NCT), single agent or multiagent chemotherapy, and neoadjuvant chemoradiation (NCRT) on survival in pancreatic cancer. Methods: Utilizing the National Cancer Database, we identified patients who underwent pancreatic resection for adenocarcinoma (2006 to 2013). Overall survival (OS) analysis was performed using the Kaplan-Meier method. Multivariable cox proportional hazard models (MVA) and propensity score matching (PSM) were developed to identify predictors of survival. For upfront surgery (UFS), OS was limited to receipt of adjuvant treatment. Results: We identified 26,563 patients who underwent pancreatic resection: UFS =23,877, NCRT =1,482, and NCT =1,204. Multiagent chemotherapy was utilized in 77% of NCT and 42% of NCRT. There was improved R0 resections associated with neoadjuvant therapy compared to UFS, however, there was no difference between NCT and NCRT. In addition, the was improved R0 with MA-NCT (PConclusions: There was improved OS associated with MA-NCT in pancreatic cancer patients compared to UFS with adjuvant therapy.
- 1 August 2019
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 10 (4) , 663-673
Neoadjuvant therapy and pancreatic cancer: a national cancer database analysis
Background: We sought to examine the impact of neoadjuvant chemotherapy (NCT), single agent or multiagent chemotherapy, and neoadjuvant chemoradiation (NCRT) on survival in pancreatic cancer. Methods: Utilizing the National Cancer Database, we identified patients who underwent pancreatic resection for adenocarcinoma (2006 to 2013). Overall survival (OS) analysis was performed using the Kaplan-Meier method. Multivariable cox proportional hazard models (MVA) and propensity score matching (PSM) were developed to identify predictors of survival. For upfront surgery (UFS), OS was limited to receipt of adjuvant treatment. Results: We identified 26,563 patients who underwent pancreatic resection: UFS =23,877, NCRT =1,482, and NCT =1,204. Multiagent chemotherapy was utilized in 77% of NCT and 42% of NCRT. There was improved R0 resections associated with neoadjuvant therapy compared to UFS, however, there was no difference between NCT and NCRT. In addition, the was improved R0 with MA-NCT (PConclusions: There was improved OS associated with MA-NCT in pancreatic cancer patients compared to UFS with adjuvant therapy.
- 1 October 2018
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 9 (5) , 894-902
Anastomotic leak and neoadjuvant chemoradiotherapy in esophageal cancer
Background: Anastomotic leaks (AL) cause significant morbidity after esophagectomy. Most patients receive neoadjuvant chemoradiation (NCR) prior to esophagectomy which has been associated with increase perioperative complications and mortality. We report on a comparison of AL rates in upfront surgical (UFS) and NCR patients. Methods: An esophagectomy database was queried for UFS and NCR patients treated between 1996 and 2015. Predictors of AL rate were identified using univariate and multivariate (MVA) analysis and propensity score matching (PSM). Results: We identified 820 patients (UFS, 288; NCR, 532). Overall AL rate was 5.4%. Decreased AL rate was observed in NCR patients on MVA (8.0% vs. 4.1%; P=0.02) but no difference was seen after PSM (7.7% vs. 4.2%; P=0.14). MVA of factors associated with decreased AL in UFS patients included distal esophageal tumors and body mass index (BMI) >25. Age, gender, year of surgery, histology, anastomotic location, and diabetes were not prognostic. Before PSM, MVA of NCR patients of factors associated with decreased AL revealed that only thoracic anastomosis was prognostic. However, this was not observed after PSM. MVA of factors associated with decreased AL in all patients revealed thoracic anastomosis, NCR, and BMI 25–30. After PSM, only distal esophageal tumors and thoracic anastomosis were prognostic for decreased AL. Conclusions: There is no difference in the AL rate between UFS and NCR patients. Decreased AL rate was observed in patients with distal esophageal tumors and thoracic anastomosis.
- 1 October 2018
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 9 (5) , 894-902
Anastomotic leak and neoadjuvant chemoradiotherapy in esophageal cancer
Background: Anastomotic leaks (AL) cause significant morbidity after esophagectomy. Most patients receive neoadjuvant chemoradiation (NCR) prior to esophagectomy which has been associated with increase perioperative complications and mortality. We report on a comparison of AL rates in upfront surgical (UFS) and NCR patients. Methods: An esophagectomy database was queried for UFS and NCR patients treated between 1996 and 2015. Predictors of AL rate were identified using univariate and multivariate (MVA) analysis and propensity score matching (PSM). Results: We identified 820 patients (UFS, 288; NCR, 532). Overall AL rate was 5.4%. Decreased AL rate was observed in NCR patients on MVA (8.0% vs. 4.1%; P=0.02) but no difference was seen after PSM (7.7% vs. 4.2%; P=0.14). MVA of factors associated with decreased AL in UFS patients included distal esophageal tumors and body mass index (BMI) >25. Age, gender, year of surgery, histology, anastomotic location, and diabetes were not prognostic. Before PSM, MVA of NCR patients of factors associated with decreased AL revealed that only thoracic anastomosis was prognostic. However, this was not observed after PSM. MVA of factors associated with decreased AL in all patients revealed thoracic anastomosis, NCR, and BMI 25–30. After PSM, only distal esophageal tumors and thoracic anastomosis were prognostic for decreased AL. Conclusions: There is no difference in the AL rate between UFS and NCR patients. Decreased AL rate was observed in patients with distal esophageal tumors and thoracic anastomosis.
- 1 October 2018
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 9 (5) , 887-893
Accuracy of endoscopic ultrasound staging for T2N0 esophageal cancer: a National Cancer Database analysis
Background: To determine accuracy of clinical staging of T2N0 esophageal cancer from the National Cancer Database (NCDB). Methods: The NCDB was accessed to identify patients with T2N0M0 esophageal cancer (adenocarcinoma or squamous cell carcinoma) treated between 2004–2013 that underwent esophagectomy. Pathologic staging was compared to clinical stage. Univariate (UVA) and multivariate analysis (MVA) was performed to identify factors related to pathologic upstaging using Cox proportional hazard ratio. Results: We identified 1,840 patients with T2N0 esophageal cancer who underwent esophagectomy as first line therapy. The median age was 67 years. The vast majority of patients were male and had distal adenocarcinomas. Clinical staging in was accurate pathologically in 30.7% of patients. While there was a trend for worse accuracy with increasing year of diagnosis, there rate of pT0–2N0 was stable. Tumor length >3 cm was significantly associated with tumor upstaging, while poor differentiation was significantly associated with nodal upstaging. UVA and MVA identified younger age, tumor length >3 cm, and poor differentiation were significantly associated with overall upstaging. Gender, tumor location, and tumor histology were not prognostic. Conclusions: Clinical staging for T2N0M0 esophageal cancer continues to remain highly inaccurate, however, rates of pT0–2N0 have steadily remained over 50%. Tumor length >3 cm and poor differentiation are strongly associated with pathologic upstaging.
- 1 October 2018
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 9 (5) , 887-893
Accuracy of endoscopic ultrasound staging for T2N0 esophageal cancer: a National Cancer Database analysis
Background: To determine accuracy of clinical staging of T2N0 esophageal cancer from the National Cancer Database (NCDB). Methods: The NCDB was accessed to identify patients with T2N0M0 esophageal cancer (adenocarcinoma or squamous cell carcinoma) treated between 2004–2013 that underwent esophagectomy. Pathologic staging was compared to clinical stage. Univariate (UVA) and multivariate analysis (MVA) was performed to identify factors related to pathologic upstaging using Cox proportional hazard ratio. Results: We identified 1,840 patients with T2N0 esophageal cancer who underwent esophagectomy as first line therapy. The median age was 67 years. The vast majority of patients were male and had distal adenocarcinomas. Clinical staging in was accurate pathologically in 30.7% of patients. While there was a trend for worse accuracy with increasing year of diagnosis, there rate of pT0–2N0 was stable. Tumor length >3 cm was significantly associated with tumor upstaging, while poor differentiation was significantly associated with nodal upstaging. UVA and MVA identified younger age, tumor length >3 cm, and poor differentiation were significantly associated with overall upstaging. Gender, tumor location, and tumor histology were not prognostic. Conclusions: Clinical staging for T2N0M0 esophageal cancer continues to remain highly inaccurate, however, rates of pT0–2N0 have steadily remained over 50%. Tumor length >3 cm and poor differentiation are strongly associated with pathologic upstaging.
- 1 August 2016
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 7 (4) , 547-555
Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer
Background: Neoadjuvant multi-agent chemotherapy and stereotactic body radiation therapy (SBRT) are utilized to increase margin negative (R0) resection rates in borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) patients. Concerns persist that these neoadjuvant therapies may worsen perioperative morbidities and mortality. Methods: Upfront resection patients (n=241) underwent resection without neoadjuvant treatment for resectable disease. They were compared to BRPC or LAPC patients (n=61) who underwent resection after chemotherapy and 5 fraction SBRT. Group comparisons were performed by Mann-Whitney U or Fisher’s exact test. Overall Survival (OS) was estimated by Kaplan-Meier and compared by log-rank methods. Results: In the neoadjuvant therapy group, there was significantly higher T classification, N classification, and vascular resection/repair rate. Surgical positive margin rate was lower after neoadjuvant therapy (3.3% vs. 16.2%, P=0.006). Post-operative morbidities (39.3% vs. 31.1%, P=0.226) and 90-day mortality (2% vs. 4%, P=0.693) were similar between the groups. Median OS was 33.5 months in the neoadjuvant therapy group compared to 23.1 months in upfront resection patients who received adjuvant treatment (P=0.057). Conclusions: Patients with BRPC or LAPC and sufficient response to neoadjuvant multi-agent chemotherapy and SBRT have similar or improved peri-operative and long-term survival outcomes compared to upfront resection patients.
- 1 August 2016
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 7 (4) , 547-555
Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer
Background: Neoadjuvant multi-agent chemotherapy and stereotactic body radiation therapy (SBRT) are utilized to increase margin negative (R0) resection rates in borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) patients. Concerns persist that these neoadjuvant therapies may worsen perioperative morbidities and mortality. Methods: Upfront resection patients (n=241) underwent resection without neoadjuvant treatment for resectable disease. They were compared to BRPC or LAPC patients (n=61) who underwent resection after chemotherapy and 5 fraction SBRT. Group comparisons were performed by Mann-Whitney U or Fisher’s exact test. Overall Survival (OS) was estimated by Kaplan-Meier and compared by log-rank methods. Results: In the neoadjuvant therapy group, there was significantly higher T classification, N classification, and vascular resection/repair rate. Surgical positive margin rate was lower after neoadjuvant therapy (3.3% vs. 16.2%, P=0.006). Post-operative morbidities (39.3% vs. 31.1%, P=0.226) and 90-day mortality (2% vs. 4%, P=0.693) were similar between the groups. Median OS was 33.5 months in the neoadjuvant therapy group compared to 23.1 months in upfront resection patients who received adjuvant treatment (P=0.057). Conclusions: Patients with BRPC or LAPC and sufficient response to neoadjuvant multi-agent chemotherapy and SBRT have similar or improved peri-operative and long-term survival outcomes compared to upfront resection patients.
- Open Access
- 1 April 2016
- Vol. 7 (2) , 206-212-212
Perioperative outcomes associated with robotic Ivor Lewis esophagectomy in patient's undergoing neoadjuvant chemoradiotherapy
Perioperative outcomes associated with robotic Ivor Lewis esophagectomy in patient’s undergoing neoadjuvant chemoradiotherapy
- 1 April 2016
- Vol. 7 (2) , 206-212-212
Open AccessPerioperative outcomes associated with robotic Ivor Lewis esophagectomy in patient's undergoing neoadjuvant chemoradiotherapy
Perioperative outcomes associated with robotic Ivor Lewis esophagectomy in patient’s undergoing neoadjuvant chemoradiotherapy
- Open Access
- 1 October 2015
- Vol. 6 (5) , 498-504-504
Outcomes of resected pancreatic cancer in patients age ≥70
Outcomes of resected pancreatic cancer in patients age ≥70
- 1 October 2015
- Vol. 6 (5) , 498-504-504
Open AccessOutcomes of resected pancreatic cancer in patients age ≥70
Outcomes of resected pancreatic cancer in patients age ≥70
- 1 March 2015
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 6 (2) , 127-132
Resected pancreatic cancer outcomes in the elderly
- 1 March 2015
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 6 (2) , 127-132
Resected pancreatic cancer outcomes in the elderly
- 29 January 2015
- Published by Springer Nature in Surgical Endoscopy
- Vol. 29 (11) , 3273-3281
Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage
We evaluated whether preoperative biliary drainage was predictive of recurrence and survival among patients with resectable pancreatic cancer.
- 29 January 2015
- Published by Springer Nature in Surgical Endoscopy
- Vol. 29 (11) , 3273-3281
Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage
We evaluated whether preoperative biliary drainage was predictive of recurrence and survival among patients with resectable pancreatic cancer.